Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry

Nature Chemistry

Volumn 7, Issue 1, 2015, Pages 73-81

  Young, Lydia M ^a   Saunders, Janet C ^a   Mahood, Rachel A ^a   Revill, Charlotte H ^a   Foster, Richard J ^a   Tu, Ling Hsien ^b   Raleigh, Daniel P ^b   Radford, Sheena E ^a   Ashcroft, Alison E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; COLLOID; MOLECULAR LIBRARY; PEPTIDE FRAGMENT; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLLOID; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; METABOLISM; MOLECULAR GENETICS; MOLECULAR LIBRARY;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; COLLOIDS; HUMANS; ISLET AMYLOID POLYPEPTIDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84961291325     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.2129     Document Type: Article

References (50)

1. Sipe, J. D. et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19, 167-170 (2012).
2. Grimster, N. P. et al. Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. J. Am. Chem. Soc. 135, 5656-5668 (2013).
3. Klabunde, T. et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nature Struct. Mol. Biol. 7, 312-321 (2000).
4. Connelly, S., Choi, S., Johnson, S. M., Kelly, J.W. &Wilson, I. A. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 20, 54-62 (2010).
5. Hamrang, Z., Rattray, N. J. W. & Pluen, A. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation. Trends Biotech. 31, 448-458 (2013).
6. Meier, J. J. et al. Inhibition of human IAPP fibril formation does not prevent ?-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am. J. Physiol. Endocrinol. Metab. 291, E1317-E1324 (2006).
7. Aitken, J. F., Loomes, K. M., Konarkowska, B. & Cooper, G. J. S. Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem. J. 374, 779-784 (2003).
8. Harroun, T. A., Bradshaw, J. P. & Ashley, R. H. Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett. 507, 200-204 (2001).
9. Woods, L. A. et al. Ligand binding to distinct states diverts aggregation of an amyloid-forming protein. Nature Chem. Biol. 7, 730-739 (2011).
10. Young, L. M., Cao, P., Raleigh, D. P., Ashcroft, A. E. & Radford, S. E. Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J. Am. Chem. Soc. 136, 660-670 (2014).
11. Hyung, S. J. et al. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-? species. Proc. Natl Acad. Sci. USA 110, 3743-3748 (2013).
12. Westermark, P. Amyloid in the islets of Langerhans: thoughts and some historical aspects. Ups. J. Med. Sci. 116, 81-89 (2011).
13. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
14. Feng, B. Y. et al. Small-molecule aggregates inhibit amyloid polymerization. Nature Chem. Biol. 4, 197-199 (2008).
15. Bieschke, J. et al. EGCG remodels mature ?-synuclein and amyloid-? fibrils and reduces cellular toxicity. Proc. Natl Acad. Sci. USA 107, 7710-7715 (2010).
16. Meng, F., Abedini, A., Plesner, A., Verchere, C. B. & Raleigh, D. P. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49, 8127-8133 (2010).
17. Howlett, D., Cutler, P., Heales, S. & Camilleri, P. Hemin and related porphyrins inhibit ?-amyloid aggregation. FEBS Lett. 417, 249-251 (1997).
18. Meng, F. & Raleigh, D. P. Inhibition of glycosaminoglycan-mediated amyloid formation by islet amyloid polypeptide and proIAPP processing intermediates. J. Mol. Biol. 406, 491-502 (2010).
19. Porat, Y., Mazor, Y., Efrat, S. & Gazit, E. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43, 14454-14462 (2004).
20. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature Struct. Mol. Biol. 15, 558-566 (2008).
21. Daubenfeld, T., Bouin, A. P. & van der Rest, G. A deconvolution method for the separation of specific versus nonspecific interactions in noncovalent protein-ligand complexes analyzed by ESI-FT-ICR mass spectrometry. J. Am. Soc. Mass Spectrom. 17, 1239-1248 (2006).
22. Sun, N., Sun, J., Kitova, E. N. & Klassen, J. S. Identifying nonspecific ligand binding in electrospray ionization mass spectrometry using the reporter molecule method. J. Am. Soc. Mass Spectrom. 20, 1242-1250 (2009).
23. Sun, J., Kitova, E. N., Wang, W. & Klassen, J. S. Method for distinguishing specific from nonspecific protein-ligand complexes in nanoelectrospray ionization mass spectrometry. Anal. Chem. 78, 3010-3018 (2006).
24. Wang, W., Kitova, E. N. & Klassen, J. S. Influence of solution and gas phase processes on protein-carbohydrate binding affinities determined by nanoelectrospray Fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 75, 4945-4955 (2003).
25. Meng, F. et al. The sulfated triphenyl methane derivative acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid polypeptide and protects against the toxic effects of amyloid formation. J. Mol. Biol. 400, 555-566 (2010).
26. Dupuis, N. F., Wu, C., Shea, J. E. & Bowers, M. T. Human islet amyloid polypeptide monomers form ordered beta-hairpins: a possible direct amyloidogenic precursor. J. Am. Chem. Soc. 131, 18283-18292 (2009).
27. Cheng, B. et al. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem. Biophys. Res. Commun. 419, 495-499 (2012).
28. Khurana, R., Uversky, V. N., Nielsen, L. & Fink, A. L. Is Congo red an amyloidspecific dye? J. Biol. Chem. 276, 22715-22721 (2001).
29. Kim, Y. S., Randolph, T. W., Manning, M. C., Stevens, F. J. & Carpenter, J. F. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J. Biol. Chem. 278, 10842-10850 (2003).
30. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug. Des. 67, 27-37 (2006).
31. Thomas, T., Nadackal, G. T. & Thomas, K. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal anti-inflammatory drugs. Exp. Clin. Endocrinol. Diabetes 111, 8-11 (2003).
32. Woods, L. A. et al. Ligand binding to distinct states diverts aggregation of an amyloid-forming protein. Nature Chem. Biol. 7, 730-739 (2011).
33. Cao, P. & Raleigh, D. P. Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. Biochemistry 51, 2670-2683 (2012).
34. Palhano, F. L., Lee, J., Grimster, N. P. & Kelly, J. W. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J. Am. Chem. Soc. 135, 7503-7510 (2013).
35. Tenidis, K. et al. Identification of a penta-and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 295, 1055-1071 (2000).
36. Petkova, A. T. et al. A structural model for Alzheimer's ?-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl Acad. Sci. USA 99, 16742-16747 (2002).
37. Young, L. et al. Monitoring oligomer formation from self-aggregating amylin peptides using ESI-IMS-MS. Int. J. Ion Mobil. Spectrom. 16, 29-39 (2013).
38. Aisen, P. et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4, 473-478 (2007).
39. Gervais, F. et al. Targeting soluble A? peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28, 537-547 (2007).
40. Necula, M., Kayed, R., Milton, S. & Glabe, C. G. Small molecule inhibitors of aggregation indicate that amyloid ? oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311-10324 (2007).
41. Valler, M. J. & Green, D. Diversity screening versus focussed screening in drug discovery. Drug Discov. Today 5, 286-293 (2000).
42. De Felice, F. G. et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A? oligomerization. FASEB J. 18, 1366-1372 (2004).
43. Ladiwala, A. R. A. et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid A? into off-pathway conformers. J. Biol. Chem. 285, 24228-24237 (2010).
44. Yang, F. et al. Curcumin inhibits formation of amyloid ? oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
45. Scherzer-Attali, R. et al. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS ONE 5, e11101 (2010).
46. Rapid Overlay of Chemical Structures (OpenEye, Scientific Software, Santa Fe, New Mexico, 2007).
47. Marek, P., Woys, A. M., Sutton, K., Zanni, M. T. & Raleigh, D. P. Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids. Org. Lett. 12, 4848-4851 (2010).
48. Giles, K. et al. Applications of a travelling wave-based radio-frequency-only stacked ring ion guide. Rapid Commun. Mass Spectrom. 18, 2401-2414 (2004).
49. Platt, G. W., Routledge, K. E., Homans, S. W. & Radford, S. E. Fibril growth kinetics reveal a region of beta2-microglobulin important for nucleation and elongation of aggregation. J. Mol. Biol. 378, 251-263 (2008).
50. Maestro, version 9.3, Schrödinger Release 2014-2 (Schrödinger LLC, New York, 2014).